Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-09
DOI
10.1038/s41598-022-06239-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic landscape of lung adenocarcinoma in East Asians
- (2020) Jianbin Chen et al. NATURE GENETICS
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
- (2020) Kang Qin et al. BMC CANCER
- Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
- (2020) Beatrice Gini et al. Journal of Thoracic Disease
- Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
- (2020) Silvia La Monica et al. Cancers
- Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
- (2019) Priyanka Bhateja et al. Cancer Medicine
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
- (2019) Qiming Wang et al. Journal of Hematology & Oncology
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies
- (2019) Jingyu Cao et al. ONCOLOGIST
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- (2018) Francisco Sanchez-Vega et al. CELL
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- GOPC - ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
- (2018) Liang Zeng et al. Journal of Thoracic Oncology
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
- (2017) Haizhen Wang et al. NATURE
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors
- (2017) Tae-Gul Lee et al. Oncology Letters
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
- (2016) Jun Wang et al. OncoTargets and Therapy
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
- (2016) Yue-Lun Zhang et al. Oncotarget
- Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
- (2016) Sun Min Lim et al. Oncotarget
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- CDK4 is an essential insulin effector in adipocytes
- (2015) Sylviane Lagarrigue et al. JOURNAL OF CLINICAL INVESTIGATION
- The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials
- (2015) Y. Hasegawa et al. ONCOLOGIST
- Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy
- (2015) Oliver Gautschi et al. Oncology Research and Treatment
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma
- (2014) Ji-Youn Han et al. LUNG CANCER
- Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
- (2013) J. K. Lee et al. ANNALS OF ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
- (2011) Lars Anders et al. CANCER CELL
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
- (2010) Elisa Benedettini et al. AMERICAN JOURNAL OF PATHOLOGY
- Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
- (2010) Sarah Park et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
- (2009) Sara E. Monaco et al. HUMAN PATHOLOGY
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
- (2008) F. Cappuzzo et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now